DefinePK

Abstract

Background:  Methotrexate (MTX) has been used for a long time as rheumatoid arthritis medication as well as for the treatment of several malignancies, including hepatoma, lymphoma, treatments of MTX and other anticancer medications are now being considered and used for various tumor treatments in order to lessen MTX-induced adverse effects and boost anticancer efficacy. As a result, the current work suggests a potentially strong therapeutic strategy for malignancies involving the use of vitamin C, ferret (Sodium Ferric Gluconate), and MTX. Methods:  Totally, 30 Albino Swiss male mice were selected and divided equally into 6 groups; negative control (no drug administered), positive control (received a single 20 mg/kg dosage of MTX, in addition to four treated groups; group 1: Vitamin C 50 mg/kg, group 2: ferrlecit 30 mg/kg, group 3: Vitamin C + MTX and group 4: ferrlecit + MTX. Samples were collected 48 hr. following the last dose of the medication. Smears were collected and Giemsa-stained. To analyze micronuclei, 1000 polychromatic erythrocytes (PECs) were counted in each animal. Results:  MTX increased cytotoxicity in the bone marrow, which was shown by a marked increase in MN formation in contrast to control. Statistically substantial decreases in percentage of micronuclei were seen in both combination pretreatment groups (MTX and Vit C) and (MTX and Fe) in comparison to mice given MTX alone. Ferrlecit was less efficient than vitamin C at preventing MTX-induced micronuclei. Conclusion:  This study concluded that the combination pretreatment has a considerable anti-toxicity impact on genetic damage. This therapeutic approach may be beneficial for future clinical cancer therapy. Keywords: Polychromatic erythrocyte; Sodium ferric gluconate; Cytotoxicity; Bone marrow